Johnson & Johnson Interim Clinical Trial Showing Promising Results
Johnson & Johnson is among the many companies that are developing COVID-19 vaccines. They published their Interim results in the New England Journal of Medicine this week. Below is an excerpt of some of their findings:
“After the administration of the first vaccine dose in 805 participants the most frequent solicited adverse events were fatigue, headache, myalgia, and injection-site pain. The most frequent systemic adverse event was fever. Neutralizing-antibody titers against wild-type virus were detected in 90% or more of all participants on day 29 after the first vaccine dose. Titers remained stable until at least day 71.
On day 14, CD4+ T-cell responses were detected in 76 to 83% of the participants with a clear skewing toward type 1 helper T cells. CD8+ T-cell responses.”
